Cardiac amyloidosis: an emerging target in HFpEF?

10' education - July 19, 2019 - Prof. van der Meer, MD, PhD - Groningen, The Netherlands

Video navigation menu

A patient case: a 74-year old male with sudden shortness of breath 0:29
Additional diagnostic test: bone scintigraphy and more 3:49
Diagnosis: HFpEF based on wild-type aTTR amyloidosis 5:11
Treatment options for ATTR amyolidosis 6:48

Educational information

This lecture by prof. van der Meer was part of a CME accredited symposium "Reshaping the future of heart failure management - Translating innovations to practice in HFpEF".

Faculty

Prof. van der Meer received both this MD and PhD cum laude from the University of Groningen in the Netherlands and worked as a visiting scientist at Harvard Medical School, Boston, MA, USA. He is a cardiologist and director of the coronary care unit at the UMCG, Groningen, The Netherlands. His research-group consists of PhD students and post-docs with various backgrounds working on (translational) research topics.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by unrestricted educational grants from Novartis, Novo Nordisk and Pfizer.

View the slides of this presentation by prof van der Meer

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.